JAMA Network
What The Study Did: In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness didn't reduce the risk of developing severe disease compared with standard care alone.
Authors: Steven Chee Loon Lim, M.R.C.P., of the Raja Permaisuri Bainun Hospital in Perak, Malaysia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2022.0189)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
